225 related articles for article (PubMed ID: 15239654)
1. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
Pasqualoto KF; Ferreira EI; Santos-Filho OA; Hopfinger AJ
J Med Chem; 2004 Jul; 47(15):3755-64. PubMed ID: 15239654
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
Nayyar A; Monga V; Malde A; Coutinho E; Jain R
Bioorg Med Chem; 2007 Jan; 15(2):626-40. PubMed ID: 17107805
[TBL] [Abstract][Full Text] [Related]
3. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
[TBL] [Abstract][Full Text] [Related]
4. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
[TBL] [Abstract][Full Text] [Related]
5. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
7. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
8. Substituted hydrazinecarbothioamide as potent antitubercular agents: synthesis and quantitative structure-activity relationship (QSAR).
Singh S; Mandal PK; Singh N; Misra AK; Singh S; Chaturvedi V; Sinha S; Saxena AK
Bioorg Med Chem Lett; 2010 Apr; 20(8):2597-600. PubMed ID: 20304645
[TBL] [Abstract][Full Text] [Related]
9. Preparation and in vitro evaluation of benzylsulfanyl benzoxazole derivatives as potential antituberculosis agents.
Klimesová V; Kocí J; Waisser K; Kaustová J; Möllmann U
Eur J Med Chem; 2009 May; 44(5):2286-93. PubMed ID: 18694614
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
11. QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.
Fernandes JP; Pasqualoto KF; Felli VM; Ferreira EI; Brandt CA
Arch Pharm (Weinheim); 2010 Feb; 343(2):91-7. PubMed ID: 20099263
[TBL] [Abstract][Full Text] [Related]
12. Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family.
Ventura C; Martins F
J Med Chem; 2008 Feb; 51(3):612-24. PubMed ID: 18176999
[TBL] [Abstract][Full Text] [Related]
13. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.
Maccari R; Ottanà R; Vigorita MG
Bioorg Med Chem Lett; 2005 May; 15(10):2509-13. PubMed ID: 15863306
[TBL] [Abstract][Full Text] [Related]
14. N-benzylsalicylthioamides: highly active potential antituberculotics.
Dolezal R; Waisser K; Petrlíková E; Kunes J; Kubicová L; Machácek M; Kaustová J; Dahse HM
Arch Pharm (Weinheim); 2009 Feb; 342(2):113-9. PubMed ID: 19137534
[TBL] [Abstract][Full Text] [Related]
15. Investigating the structural basis of arylamides to improve potency against M. tuberculosis strain through molecular dynamics simulations.
Punkvang A; Saparpakorn P; Hannongbua S; Wolschann P; Beyer A; Pungpo P
Eur J Med Chem; 2010 Dec; 45(12):5585-93. PubMed ID: 20888672
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents.
De P; Koumba Yoya G; Constant P; Bedos-Belval F; Duran H; Saffon N; Daffé M; Baltas M
J Med Chem; 2011 Mar; 54(5):1449-61. PubMed ID: 21309577
[TBL] [Abstract][Full Text] [Related]
17. Relationships between molecular properties and antimycobacterial activities of steroids.
Rugutt JK; Rugutt KJ
Nat Prod Lett; 2002 Apr; 16(2):107-13. PubMed ID: 11990426
[TBL] [Abstract][Full Text] [Related]
18. Researches concerning the synthesis and antituberculosis action of some new sulphacetamide derivatives.
Ungureanu M; Diculencu D; Stirbu CA
Rev Med Chir Soc Med Nat Iasi; 2006; 110(2):456-9. PubMed ID: 17802961
[TBL] [Abstract][Full Text] [Related]
19. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides.
Manvar A; Malde A; Verma J; Virsodia V; Mishra A; Upadhyay K; Acharya H; Coutinho E; Shah A
Eur J Med Chem; 2008 Nov; 43(11):2395-403. PubMed ID: 18328603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
